What Omegaven Treats: Main Uses and Benefits

Omegaven is applied across domains where additional symptomatic support is needed and is commonly used across conditions presenting with acute episodes. Its primary therapeutic use is in pediatric patients with parenteral nutrition-associated cholestasis (PNAC). This is considered relevant in conditions involving inflammatory or irritative processes linked to organ-specific functional stress.

Omegaven is applied in addressing the symptomatic burden of PNAC, a condition characterized by periods of heightened symptoms. The core therapeutic function is relevant for easing the discomfort and may play a role in managing systemic imbalance when standard nutritional support is not appropriate. The treatment is used in situations involving certain distressing symptoms such as elevated bilirubin levels, supporting the overall symptomatic management. “It provides supportive relief when symptoms interfere with routine activities,” and helps maintain a sense of stability when symptoms are more noticeable. Omegaven contributes to easing the overall symptom load and may assist with maintaining functional stability during phases of increased distress or discomfort.

Quick Fact: Used for managing Symptoms linked to Organ-Specific Functional Stress

The eligibility for Omegaven is strictly restricted to a specific patient group, as defined by regulatory bodies. It is indicated for pediatric patients who have developed Parenteral Nutrition-Associated Cholestasis (PNAC). Use for the prevention of PNAC is not indicated. The regulatory data supporting the medicine’s primary indication does not include the adult or older adult (geriatric) populations, where use is not established. Caution is required when administering Omegaven to infants and neonates, particularly regarding the infusion rate, and to patients with existing renal impairment due to the risk of aluminum toxicity.

Population Status	Condition/Restriction
Contraindicated	Known hypersensitivity to fish or egg protein.
Contraindicated	Severe hemorrhagic disorders.
Contraindicated	Severe hypertriglyceridemia (serum triglycerides > 1,000 mg/dL).
Use with Caution	Renal impairment, due to aluminum toxicity risk.

The medicine is further classified by some regulators for use during pregnancy and lactation as having no evidence on safety, advising use only when strictly necessary. Patients must be monitored for triglyceride clearance, and the infusion may be temporarily stopped if lipid elimination is impaired.

Omegaven's official interaction profile is defined by a primary pharmacodynamic effect and specific administration restrictions documented in regulatory labeling. The active fish oil triglycerides component has the potential to inhibit platelet aggregation and prolong bleeding time.

Pharmacodynamic Interactions

Co-administration with other medicines that affect hemostasis, such as antiplatelet agents and anticoagulants, may result in an additive effect. Regulatory authorities require that bleeding time be monitored periodically when this medicine is used concomitantly with these product categories.

Due to this potential pharmacodynamic interaction with the clotting cascade, the medicine is formally contraindicated in patients diagnosed with severe hemorrhagic disorders. This patient-specific restriction is directly tied to the potential for the active component to increase bleeding risk.

Administration and Incompatibility Restrictions

A risk of physical incompatibility exists when Omegaven is co-administered with certain solutions. This includes specific concentrations of heparin or the addition of polyvalent cations, such as calcium, which can lead to emulsion destabilization. Compatibility with any co-infused solutions or admixtures must be verified before administration to maintain stability. Official regulatory documentation does not list specific pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, nor are there documented interactions with food, alcohol, or herbal products.

Modulating Inflammatory Eicosanoid Pathways

The mechanism of Omegaven is rooted in the incorporation of its active components, Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA), into cell membrane phospholipids. This structural change causes a competitive shift in the eicosanoid synthesis pathway, where EPA replaces Arachidonic Acid (ARA) as the substrate for COX and LOX enzymes. This enzymatic shift favors the creation of Series-3 eicosanoids, inflammatory mediators that demonstrate altered signaling properties compared to Series-2 eicosanoids. This action modulates the systemic eicosanoid profile.

Driving Active Resolution and Immunomodulation

Beyond reducing pro-inflammatory signals, Omegaven's mechanism contributes to the initiation of resolution pathways. The incorporated EPA and DHA are metabolized into specialized molecules, primarily Resolvins and Protectins, known as Specialized Pro-Resolving Mediators (SPMs). These SPMs signal immune cells for the termination of the inflammatory response and engage mechanisms that promote the clearance of cellular debris. This process is involved in achieving systemic immunomodulation, which is involved in mitigating inflammation within organ systems. The full extent of this effect is time-dependent, requiring sustained incorporation into cell structures.

Omegaven is an injectable lipid emulsion administered to pediatric patients intravenously as a source of calories and essential fatty acids, typically in the context of parenteral nutrition (PN)-associated cholestasis (PNAC).

Administration and Preparation

Omegaven is a single-dose emulsion for central or peripheral intravenous infusion and may be administered either directly from its original container or as an admixture in a PN container.

• Prior to use, correct severe fluid and electrolyte disorders and establish a baseline serum triglyceride level. The bottle should be gently inverted before use and visually inspected for particulate matter or discoloration. The emulsion must be homogeneous and the container undamaged.
• Infusion Rate: The initial rate of intravenous infusion should not exceed 0.05 mL/minute for the first 15 to 30 minutes. If tolerated, the rate is gradually increased; the maximum infusion rate should not exceed 1.5 mL/kg/hour, which corresponds to 0.15 g/kg/hour.
• Infusion Duration: The recommended duration for infusion is between 8 and 24 hours, based on the patient's clinical situation.
• Admixing: When preparing a PN admixture, strict aseptic techniques must be followed. Solutions with an osmolarity of 900 mOsm/L or greater must be infused through a central vein. A 1.2 micron in-line filter should be used during administration.

Dosing

Omegaven dosing is highly individualized, depending on the patient's age, body weight, tolerance, clinical status, energy requirements, and other nutritional sources. The recommended daily dose (and maximum daily dose) for pediatric patients is 1 g/kg/day. Treatment is typically continued until the direct or conjugated bilirubin level is less than 2 mg/dL or until the patient no longer requires PN.

Omegaven: Recent Clinical Evidence

Summary of Findings

Studies have examined the use of Omegaven (an intravenous lipid emulsion containing fish oil) in various patient populations requiring parenteral nutrition (PN). Research primarily focuses on its potential role in reducing the risk of PN-associated liver disease (PNALD), particularly in infants and children.

The mechanism of action involves supplying essential fatty acids while replacing or modifying conventional soy-based lipid emulsions, which contain higher levels of pro-inflammatory compounds and phytosterols. Research has investigated how this change in lipid source affects liver function and inflammation markers.

Key Study Areas

Parenteral Nutrition-Associated Liver Disease (PNALD)

Clinical data, primarily from observational studies and small randomized trials, have explored the effect of Omegaven use on PNALD development and progression in pediatric patients. Studies suggested that using fish oil-based lipid emulsions may be associated with improved markers of liver function and a lower incidence of cholestasis in certain high-risk patient groups.

Safety and Tolerability Profile

Research findings regarding the treatment's safety profile have been reported across numerous trials. Overall, Omegaven is generally reported as being well-tolerated. Common reported adverse events include mild elevations in triglycerides, which are typically managed by adjusting the infusion rate or dosage. Serious adverse events were reported infrequently, and monitoring protocols for liver function and platelet count were utilized in trial settings.

Comparative Studies

Some research compared outcomes between Omegaven and standard soy-based lipid emulsions. These studies documented differing inflammatory profiles and potentially distinct effects on liver health. Findings indicated that in patients with existing PNALD, replacing standard lipid emulsions with Omegaven was associated with measurable improvements in bilirubin levels.

Key Studies & References ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids (Position Paper on ILEs and Hepatotoxicity)

Common questions about Omegaven (FAQ)

Q: How quickly does Omegaven start to have an effect?

Clinical guidance on the administration of this intravenous lipid emulsion suggests that the full therapeutic effects, such as improvement in certain liver markers, typically begin to show 4 to 6 weeks after the start of administration. The full therapeutic extent is considered time-dependent, consistent with how the active ingredients are described to work.

Q: Is Omegaven used for conditions other than just long-term feeding issues?

According to official regulatory documents, Omegaven is formally indicated only for pediatric patients who have established Parenteral Nutrition-Associated Cholestasis (PNAC). It is administered as a source of calories and essential fatty acids within the context of total parenteral nutrition (TPN). The approved indication for Omegaven is specifically for treatment, and not for the prevention of PNAC.

Q: Can Omegaven be given to newborn babies?

The product is approved for use in the pediatric population, which includes newborns and infants. However, official warnings specifically caution that for neonates and infants, there is a risk of clinical decompensation if the infusion is administered too rapidly. This population requires careful monitoring of the infusion rate to manage the documented risks.

Q: Are there any long-term effects of using Omegaven for extended periods?

Official labeling includes a warning about the risk of Aluminum Toxicity with prolonged use, especially in patients with existing kidney problems (renal impairment). Monitoring of liver function and essential fatty acid status is typically part of the long-term management protocols.

Q: How often is Omegaven typically administered?

Omegaven is a single-dose injectable emulsion. The total required daily amount is infused over an extended period.

Q: Are there any religious or dietary restrictions related to Omegaven's ingredients?

The official product information states that the drug is formally contraindicated (should not be used) in individuals who have a known hypersensitivity to fish or egg protein. Patients may wish to confirm how these components align with any personal dietary or religious restrictions.

Q: Can Omegaven be administered at home?

The administration requires adherence to strict requirements, including the use of specialized equipment and precise infusion rates. Due to the precise nature and specialized equipment required for infusion, administration typically takes place under professional supervision.

Q: Do studies suggest Omegaven provides better nutritional support than standard lipid products?

Official regulatory documents acknowledge Omegaven as an effective source of calories and essential fatty acids. While research exists comparing it to other intravenous lipid emulsions (ILEs), the official label does not make a direct claim of superior general nutritional support.

Q: How is Omegaven manufactured or sourced?

The active ingredient is highly refined fish oil triglycerides, concentrated lipids derived from marine sources. The emulsion also contains non-active components like egg phospholipids (for stability) and glycerin (for tonicity). Detailed production steps are not generally included in the public regulatory documentation.

Q: What are the warning signs of a serious reaction to Omegaven?

Healthcare providers are required to monitor for serious reactions such as Hypersensitivity Reactions and Fat Overload Syndrome. Warning signs that have been reported with IV fat emulsions include common symptoms like fever, chills, headache, nausea, and vomiting. Signs associated with a severe allergic reaction, such as difficulty breathing, are documented as reasons to seek emergency assistance.

Q: Why do doctors check bloodwork before and during Omegaven use?

Official guidance requires regular monitoring of bloodwork for specific safety and efficacy markers. This includes checking serum triglyceride levels to observe the rate of lipid clearance, and tracking conjugated bilirubin levels to help determine the treatment duration.

Q: Do clinical trials support the use of Omegaven in long-term care?

Official documents confirm Omegaven is approved for use in pediatric patients with PNAC who are dependent on parenteral nutrition (PN). The indication for PNAC is typically associated with the need for sustained nutritional support.

Q: Is Omegaven considered a high-risk medication?

Regulatory documents define specific situations where the product is contraindicated, such as in cases of severe hypertriglyceridemia. Furthermore, official warnings detail serious risks, including Fat Overload Syndrome and Aluminum Toxicity. These documented risks are used to guide ongoing monitoring and administration protocols.

Q: Is it possible for Omegaven to cause weight gain?

Omegaven is administered as a source of essential calories (energy) and essential fatty acids. Clinical data reviewed by regulatory bodies indicated that pediatric patients receiving the product achieved age-appropriate growth, which is the intended nutritional outcome.

Q: Is there a generic version of Omegaven available?

Omegaven is the registered trade name for this specific intravenous lipid emulsion containing fish oil triglycerides. Currently, the drug product is generally referred to in official documentation by its single brand name.

Q: Does Omegaven contain any sugar or carbohydrates?

The active ingredients are fish oil triglycerides (fat) and the formulation includes egg phospholipids and glycerin. Omegaven is the designated lipid source in Total Parenteral Nutrition (TPN), which typically uses separate solutions to provide sugar (dextrose) and protein (amino acids).

Q: What happens if a dose of Omegaven is missed or delayed?

Official patient information states that a doctor or healthcare provider should be contacted to determine the appropriate next steps if a dose is missed or delayed.

Q: What is the shelf life of Omegaven before it is used?

According to official regulatory information, the approved shelf life (expiration dating) for Omegaven before it is mixed into other solutions is stated as 18 months from the date of manufacture. It must be stored below 25 C (77 F) and must not be frozen.

Q: How does Omegaven affect the body's cholesterol levels?

Official monitoring and safety information focuses on managing the body's triglyceride levels, specifically to prevent severe hypertriglyceridemia (excessively high blood fat levels). Changes to cholesterol levels are not typically listed in the documented adverse reaction profile for this product.

Q: How is the safety of Omegaven tracked after it's approved?

The official drug label includes instructions for healthcare professionals to report any SUSPECTED ADVERSE REACTIONS to the FDA’s MedWatch reporting system or directly to the manufacturer. This mechanism is the formal process used to track the safety of medicines after they are made available to the public.

Q: What are the common injection site reactions described for Omegaven?

Patient guidance information states that redness, swelling, or pain at the injection site should be reported to a healthcare provider.

How to Store and Dispose of Omegaven

Omegaven injectable emulsion must be stored according to strict regulatory specifications to ensure stability. The product must be stored below 25 C (77 F) and must not be frozen; the product must be discarded if it has been frozen. It must also be kept out of the sight and reach of children.

Omegaven is a single-use container. Any unused portion remaining in the bottle must be discarded after a single administration. If mixed into a Parenteral Nutrition (PN) admixture, the solution must be protected from light. Admixtures can be stored under refrigeration for up to 24 hours.

For disposal, unused or expired Omegaven should not be thrown into household waste or poured down a sink. Disposal must follow established pharmaceutical waste handling procedures; patients should consult their pharmacist for specific instructions.